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Abstract-The study aimed to analyze the effect of Torbangun to reduction uric acid in woman with hypercholesterolemia. Design 
experiment used in this study was pre and post test controlled group design. The first step of this study was analyzed bioactive compound 
of torbangun aqueous extract. The next step was administired orally of Torbangun extract to control and woman with 
hypercholesterolemia for 30 days, with 30 subjects placed in two groups, viz, experimental (CC group) and placebo (PC group). The 
first group received one capsules of CC (each capsule contains 500 mg extract) while the second group received one capsules of PC 
(comprised of 500 mg fillers) one times daily for both groups. Uric acid (UA) and total cholesterol (TC) were measured in the first and 
the end of intervention. Oral administired of Torbangun extract exhibited reduce of hyper uric acid and hyper total cholesterol in woman 
with hypercholesterolemia. Data were analyzed with paired sample t test with 95% significance level. The results show that there was 
significant decrease in UA and TC on day 30, compared to control (PC group).  In CC group, the capsules significant reduction in UA 
levels (p=0.001) and TC levels (p=0.000). Studies clearly demonstrated that Torbangun (Coleus amboinicus Lour) aqueous extract 
possesses antihyperuricemic activity in woman with hypercholesterolemia.  
 
Index Terms- uric acid, antihyperuricemic, torbangun extract  
 
I. INTRODUCTION 
Hyperuricemia is abnormal high level of uric acid, it is a common metabolic disorder with a worldwide distribution. It has been 
considered as an important risk factor for gout [1]. Hyperuricemia, a concentration of urate in serum above the limit of solubility (≤ 7.0 
mg/dL), is the most important risk factor of increased uric acid production, impaired renal uric acid excretion, or a combination of these 
mechanisms [2]. Clinically reported, the key factor uric acid is related not only to an increased risk of gout, but also to an increased risk 
of cardiovascular disorder, nephrolithiasis, diabetes, obesity, and dyslipidemia [3]. The mammals and birds will store their excess fat 
not only in their adipose tissue, but also in their liver and serum (triglycerides), often in association with the development of insulin 
resistance and elevated blood pressure [4]. The recent studies suggest a role for nucleic acid metabolism, in which stimulation of 
adenosine monophosphate (AMP) deaminase promotes fat storage and insulin resistance, whereas activation of AMP activated protein 
kinase stimulates fat degradation and decreases gluconeogenesis [5]. A key factor that appears to promote fat storage is the AMP 
deaminase product, uric acid [6]. Here we will briefly discuss the studies incriminating uric acid in these conditions.  
Medicinal plants are believed to be an important sources of new chemical substances with potential therapeutic effect. Plant based 
medicines are gaining prominence in treatment of metabolic disease. Many flavonoid containing plants serve as a hidden wealth of 
diabetes and dyslipidemia control. Torbangun is an aromatic shrub widely distributed in Indonesia. The literature survey revealed 
torbangun leaf extract to have an antioxidant property. The leaves of torbangun have been used in Indonesian traditional medicine for 
treatments of antihyperglicemia and antihyperlipidemia [7]. The hyperuricemia is present in 5–30% of the general population and seems 
to be increasing worldwide. Therefore, there is an obvious need for therapeutic strategies that could act on the physiological regulation 
of uric acid levels and prevention of uric acid-related diseases. Herein, we reported the hypouricemic effect of torbangun in woman with 
hypercholesterolemia. 
II. IDENTIFY, RESEARCH AND COLLECT IDEA 
2.1. Plant materials.  
Torbangun (Coleus amboinicus Lour) were collected from a traditional market in Jakarta Indonesia, in the months of Desember 
2017. The leaf separated, cleaned, air-dried, coarsely powdered, and subjected for Soxhlet-extraction by using aqueous. Powder 
weighing 70 g was extracted with 600 ml of aqueous for 72 h for each batch. The solvent was recovered using rotovapor. The semisolid 
mass obtained was concentrated under reduced pressure and stored in an air tight container[8]. Each 500 mg Coleus amboinicus Lour 
capsule (CC) containing 90 % dry extract of CC plant  and 10 % filler and was registered for sale in Indonesia 
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2.2. Design study  
This study was conducted between Oktober 2017 – Oktober 2018, and was a double-blind design, randomized controlled 
clinical trial, conducted in woman with hypercholesterolemia   in Cawang East Jakarta, Indonesia. The Ethics Committee of the Faculty 
of  Medicine, Christian University of Indonesia, East Jakarta, Indonesia reviewed the research protocol used and approved it (Reg. no. 
127/PT02. FK/ETIK/2012). 
Inclusion criteria for all woman was long-term treatment by Torbangun (Coleus amboinicus Lour)  leaf aqueous extract in woman with 
hypercholesterolemia with an increased TC > 200 mg/dL, aged over 30 years and willing to give informed consent. Exclusion criteria 
were suffering from other confounding diseases, including chronic inflammatory diseases, acute infections. 
Thirty woman were randomly assigned into two groups: CC group and the PC group. This study was a randomized double-blind placebo-
controlled clinical trial, with 30 subjects placed in two groups, viz, experimental (CC group) and placebo (PC group). The first group 
received one capsules of CC (each capsule contains 500 mg extract) while the second group received one capsules of placebo (comprised 
of 500 mg fillers) one times daily, for 30 days for both groups. TC was measured by Autocheck, multi monitoring system. The body 
mass index, and compliance of all the subjects were assessed using a questionnaire at the end of study. Blood samples were collected 
twice at baseline and day 30 of study. The values of UA was determined from blood cholesterol. The UA was measured using methods 
by assays an automated chemistry analyzer.  
 
2.5. Statistical analysis: 
The collected data were analyzed using the statistical software SPSS, version 22. (SPSS Inc., Chicago, IL, USA) and the results were 
expressed as the mean ± SD.  The changes in anthropometric measurements and blood parameters of the participants between the 
beginning and end of the trial were compared by paired sample t test with 95% significance level. Differences between the data were 
considered significant at P<0.05. 
III. RESULTS 
All the woman with hypercholesterolemia (15 woman in CC group and 15 woman in PC group) completed the study (Fig.1). 
Compliance was good, with all the Torbangun  leaf aqueous extract capsule prescribed being consumed during the study period. No side 
effects were reported from participans during the study period.  
 
                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitment and  assessed for  eligility (n=52) 
Eligible (n=30)  
 
Enrollment 
Randomized (n=30)  
Allocation 
One capsule of CC one time a day 
for 4 weeks  
 
One capsule of PC one time a day 
for 4 weeks  
 
Analysis 
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Figure 1. Participant’s flow diagram 
 
Biochemical and general characteristics of participants at the beginning and end of the study are shown in Table 1. There were 
no significant differences between group in BMI and BP in the beginning of the study and after 4 weeks of intervention (p= 0.151) and 
(p=0,989 and p=0,675). Uric acid and total cholesterol levels significantly change in CC group after intervention compared to their 
baseline value (p=0,001 and p=0.000), are shown in Table 2. 
 
 
Table 1 
 
BMI, TC, UA and BP Characteristics of the woman with hypercholesterolemia at baseline and after intervention 
 
Variabel Mean N Std. Deviation 
BMI 
Before 25.298 15 3.500 
After 24.612 15 3.805 
UA 
Before 6.267 15 1.222 
After 5.640 15 1.202 
TC 
Before 258.800 15 28.917 
After 224.333 15 35.361 
BP Sistole 
Before 137.133 15 16.221 
After 137.200 15 12.924 
BP Diastole 
Before 78.267 15 8.216 
After 79.533 15 8.114 
               BMI: body mass index; TC: Total Cholesterol, BP: Blood Pressure; SD: Standard Deviation  
 
Base on results of BMI, UA and TC respondents there were decreased, but BP levels were slightly increased. The changes in 
BMI, BP, TC and UA between the beginning and end of the trial were compared by paired samples t test. 
 
 
Table 2.  Paired samples t test 
 
Hipotesis 
Paired Differences 
t df 
Sig. (2-
tailed) 
Result 
Mean 
Std. 
Deviation 
BMI_before - BMI_After .686 1.751 1.519 14 0.151 No Significant  
UA_before - UA_After .627 .555 4.375 14 0.001 Significant 
TC_before - TC_After 34.467 20.815 6.413 14 0.000 Significant 
BP sistole_Before – BP sistole 
_After 
-.067 17.950 -.014 14 0.989 
No Significant  
BP diastole_Before – BPdiastole 
_After 
-1.267 11.467 -.428 14 0.675 
No Significant  
BMI: body mass index; TC: Total Cholesterol, BP: Blood Pressure; SD: Standard Deviation 
 
Table 2 illustrated changes in paired samples t test, the levels of BMI, UA, TC and BP of studied group and during 4-weeks 
period of study.  No significant differences were in BMI and BP between two study groups. The results show that there were significant 
decrease in UA and TC on day 30, compared to control (P group).  In CC group, the capsules strongly significant reduction in UA levels 
(p < 0.05).  
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IV. DISCUSSION 
The development of renal diseas may have direct role of uric acid.  Oxonate, a selectively competitive uricase inhibitor, blocks 
the effect of hepatic uricase, and produces hyperuricemia in rodents [9].  The aim of the present study is to investigate hypouricemic 
effect of torbangun aqueous extract on the uric acid level in woman with hypercholesterolemia. This randomized, double-blind, placebo-
controlled 4 week trial represents a uric acid comparison between woman with hypercholesterolemia  individuals taking a 500 mg/day 
of Torbangun leaf aqueous extract capsule (CC) versus a placebo group (PC). The biomarkers examined included uric acid, total 
cholesterol, blood pressure.  Body mass index was measured of body fat based on high and weight that applies to woman. The present 
study was conducted to assess the antihyperuricemic activity of Torbangun leaf aqueous extract in woman with hypercholesterolemia. 
However, of these 52 volunteers, 22 could not participate throughout the entire study period and were excluded from the study. The 
remaining 52 volunteers were assigned to either the control or trial group. The volunteers in both groups were also given 
information/educational intervention from the physicians and gave informed consent. None of the volunteers had either diabetic, 
hypertension, hepatic or renal diseases. All of the volunteers in both groups were educated on diet control and doing exercises. Therefore, 
it could be considered that there were similarities between the volunteers assigned to each group.  
This work also indicate that the capsule extract, especially the dose of trial 500 mg after 4 weeks of intervention produced more 
alleviating effects. This observation confirms the fact that Torbangun leaf aqueous  extract capsule of plants are generally known for 
their high contents in chemical compounds capable of producing biological activities [10]. With regard to the lowering uric acid  
concentrations in woman with hypercholesterolemia, it could be proposed that Torbangun may act by (1) stimulating biological activity 
by producing satiety and reducing food intake [11], (2) polyphenols and a water extract of these polyphenols exhibited cholesterol-
lowering abilities in vitro and vivo [12], (3) reduce the re-absorption of bile cholesterol[13]. (4) reduce uric acid product. Base on results 
of body mass index no significant decrease, and the blood pressure of sistole and diastole levels were slightly increased, but the uric 
acid and  total cholesterol level of  respondents there were strongly significant decreased.  
Studies are warranted to evaluate the effect of Torbangun leaf aqueous extract on human with hyperglicemia. Despite in vitro 
and in vivo evidence of the uric acid and cholesterol-lowering benefits of polyphenols, there is not enough clinical evidence to support 
these results. Therefore, it is important for additional studies to be conducted to detect the specific mechanisms of polyphenols for 
lowering uic acid and cholesterol. These alleviating effects clearly denote the antihyperuricemic and antihypercholesterolemic potential 
of Torbangun. It could also be suggested that the effect of Torbangun leaf aqueous extract capsule pass through a decrease in intestinal 
cholesterol absorption or a decrease in the biosynthesis of cholesterol specifically by decreasing the activity of HMG-CoA reductase 
inhibitors and the AMP deaminase product, uric acid[14]. Although Torbangun leaf aqueous extract revealing antihyperuricemic 
potential, further phytochemical investigations are needed to identify their active constituents.  
V. CONCLUSION 
In conclusion, the present study indicates treatment of woman with hypercholesterolemia by administration of Torbangun (Coleus 
amboinicus Lour) leaf aqueous extract capsule, for four consecutive weeks could restore the biotransformation by shifting the balance 
of uric acid and cholesterol metabolism. The extract showed significant antihyperuricemic with very crucial effects on cholesterol levels. 
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